Thursday, July 2

**ORAL SESSIONS 09.00-10.30**

**PL4**  
Plenary: Consequences of an Evolving Epidemic  
Chairs: Michael H. Merson, Heydee Pellegrini  
Venue: Arena  
Time: 09.00-10.30

- 485 From personal to global survival  
  Javier Luis Hourcade Belloque
- 486 From personal to global survival  
  Naisaiedet Maina
- 487 Priorities for public funds: crises in national leadership?  
  Omwony D’Owok
- 488 Priorities for public funds: crises in national leadership?  
  Marina Mahathir
- 489 Human rights: consequences for the epidemic HIV  
  Mary Robinson

**PPL4**  
Plenary: Biomedical Advances in HIV Research  
Chairs: Kim Nichols, F. Waldvogel  
Venue: Session Hall I  
Time: 09.00-10.30

- 490 How viruses cause immunosuppression  
  Rolf Zinkernagel
- 491 The significance of virus subtypes for epidemiology and pathogenesis  
  Jaap Goudsmit
- 492 How HIV functions, multiplies and causes disease: possible new approaches to therapy  
  Robert Gallo

**11.00-12.30**

**A41**  
Vaccine Trials in Humans  
Chairs: Vina Churdboonchart, Andrei Kozlov  
Venue: Session Hall VII  
Time: 11.00-12.30

- 493 Vaccine trials in humans  
  Larry Corey
- 494 Induction of immune responses  
  Kent Weinhold
- 495 CD8+CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost  
  Thomas Evardt; L. Corey; M.L. Clements-Mann; K. Weinhold; R.B. Belshe; J.L. Excler; A.M. Duliege, USA
- 496 A phase I trial of vaccinia-env/gag/pol (TBC 3B) given by alternative routes, boosted with rgp120  
  Michael C. Keefer*; M.J. McElrath; K. Weinhold; G.J. Gorse; M. Mulligan; D. Francis; D. Panicali, USA
- 497 HIV-1 cross-clade-lymphoproliferative responses following immunization with recombinant Gp120 SF2  
  Thippawan Chuenchitra*; S. Ratto-Kim; M. De Souza; K. Rungruengthanakit; S. Nitayaphan; C. Khamboonruang; C. Chuenchitra; R.A. Michael; F. Sinangil; A.M. Duliege; J.G. McNeil; D.L. Birx, Thailand
- 498 NIAD funding opportunities for AIDS vaccine research: new strategy and programmes  
  Steve Bende

**NOTES**

---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
---
ORAL SESSIONS 11.00–12.30

B41 Care in Special Populations

Chairs: Shaun Mellors, Robert Shearer
Venue: Session Hall III
Time: 11.00–12.30

499 Virologic response to antiretroviral therapy among HIV-infected injection drug users
Wafaa El-Sadr*; Sharon Mannheimer; J. Flowers; H. Safavi; J. Curtis, USA
32407

500 Barriers to HIV antiretroviral therapy among injection drug users in settings with and without universal health insurance coverage
David Celentano*; R.S. Hogg; D. Vlahov; S.A. Strathdee; R.D. Moore; A. Palepu; S. Cohn, USA
42285

501 Prisons and public health: Emerging issues in HIV treatment adherence
Linda Frank, USA
32408

502 Continuity of medical care and risk of incarceration in HIV+ and HIV- high risk women
Mary Sheer*; Timothy Flanigan; T.P. Flanigan; J. Allsworth; J. Hogan; M.D. Stein; D. Vlahov; E. Schoenbaum, USA
32411

503 Health status and co-morbidity of HIV+ and HIV- out-of-treatment injection drug users (IDUs)
Frederik Altice*; K. Khooshnood; K.M. Blankenship; C.T. Ream; M. Kravitz, USA
32409

504 Pozifit, positively fit: A prospective, pilot project in community-based HIV rehabilitation services
Gerry Bally*; G.R. Murphy, Canada
42400

505 Palliative care for HIV-infection in a skilled nursing facility
Peter A. Seley*; K.P. Fennie; S. Molde; J. Constantino, Sr.; P. Wetherill; L. Goldman; C. Kennedy, USA
22427

B42 Predictors of Response to Antiretroviral Treatment

Chairs: Jonathan Anderson, Peter Mugyenyi
Venue: Session Hall IV
Time: 11.00–12.30

506 HIV RNA, CD4+ cell count, and immune activation markers predict HIV-related wasting prior to AIDS in the Multicenter AIDS Cohort Study (MACS)
Robert H. Lyles*; A.M. Tang; J.W. Mellors; J.B. Margolick; B.R. Vischer; J.P. Phair; N.M.H. Graham, USA
32167

507 HIV serum RNA, CD4 cell numbers and risk for clinical endpoints in a case-cohort study of ACTG 175
David Katzenstein*; S. Kim; M. Hughes; S. Hammer; V. Degruttola, USA
12124

508 Phosphorylation rate of 3’-azidothymidine in maternal and fetal peripheral blood mononuclear cells at term
Riad Agbaria*; J. Barak; E. Manor; J. Balzarini, Israel
42258

509 Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and antiretroviral experienced HIV+ patients
P.G. Hoggard*; David J. Back; S.E. Gibbons; J. Lloyd; M.G. Barry; S.H. Khoo; C. Loveday, UK
42260

510 The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma
Richard M. W. Hoetelmans*; M.H.E. Reijers; G.F. Weberling; S. Furriaans; F.M.A. Lange, The Netherlands
42259

511 Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period
Richard M.W. Hoetelmans*; R.P.G. Heeswijk, Van; P.L. Meerhorst; F.W. Mulder; W.A. Scheele; F.H. Beijnen, The Netherlands
42261

512 Saliva as a possible specimen for monitoring compliance and plasma levels in patients treated with indinavir (IDV)
Patricia W.H. Hugen*; D.M. Burger; A.M.W. Hoetelmans; K. Brinkman; P.L. Meerhorst; J. W. Mulder; P.P. Koopmans, The Netherlands
32330

B43 HIV-infection in Children

Chairs: Luke Chipperfield, Connie Mwaise Osborne
Venue: Arena
Time: 11.00–12.30

513 Markers for diagnosis and for monitoring therapy in children
John Ziegler
43555

514 Clinical management in the North
Sandra Burchett
13212

515 Clinical management in resource-poor settings
Suniti Solomon
23507

516 Palliative care for children
Jim Oleske
13281

C41 Trends and Patterns of HIV Epidemics

Chairs: Jordi Casabona, Euclides Castilho
Venue: Session Hall V
Time: 11.00–12.30

Kenrad Nelson*; S. Eiutrakul; D.D. Celentano; C. Beyrer; S. Kuntolbutra; C. Khamboonruang, USA
13212

Philip Renzullo*; H. Bacellar; R.P. Garner; D.L. Bix; J.G. McNeil, USA
23507

519 Risk for HIV-1 seroconversion in the Ugandan people’s defense forces
Kathleen George*; D. Horn; J. McGrath; J. L. Johnson; P. Mugyenyi; R. Mugerwa; J. Ellner, Uganda
13281

520 Annual HIV incidence decreased among persons with sexually transmitted diseases (STD) in Italy between 1988 and 1994
Barbara Suligoi*; M. Giuliani; M. Balducci; N. Galai, Italy
43508

521 HIV in the Philippines: Analysis of data from the National HIV Sentinel Surveillance System
Maria Consoria Lim-Quizon*; M.C.R. Roces; W. Cuenco; A.E. Ghee; G. Poumerol; S. Omi, Philippines
13179

522 The HIV/AIDS epidemic in Europe: Changing trends and new challenges
Francoise F. Hamers*; A.M. Downs; A. Infuso; J.B. Brunet, France
13179
JUNE 30
JULY 1
JULY 2
JULY 3

CONFERENCE WORKBOOK

Thursday, July 2

ORAL SESSIONS 11.00-12.30

C42 STD/HIV Interaction

| Chairs: | Subhash Hira, Judy Wasserheit |
| Venue: | Session Hall VI |
| Time: | 11.00-12.30 |

523 Overview of the STD-HIV Interaction
King Holmes

524 Population attributable risk of HIV incidence associated with STD symptoms, Rakai Community-Based Study, Uganda
Maria J. Wawer*, N.K. Sewankambo, D. Serwadda, L. Paxton, N. Kiwanuka, C.J. Li, R.H. Gray, USA

525 STD control for HIV prevention in the US.
Is there likely to be an impact?
William Kasser*, K.L. Irwin, M.L. Kamb, H. Weinstock, R.W. Steketee, M. St. Louis, J. Wasserheit, USA

526 Estimating the effect of treating sexually transmitted diseases (STDs) on HIV transmission
Richard Rothenberg*, J. Wasserheit, M. St. Louis, USA

527 Heterosexual and perinatal transmission of HIV-1: Associations with bacterial vaginosis (BV)
Taha Taha*, N. Kumwenda, G. Liomba, J. Chiphangwi, D. Hoover, G. Dallabetta, P. Miotti, USA

528 A randomized trial of STD control during pregnancy in Rakai, Uganda: Impact on maternal and infant health
Ronald H. Gray*, G. Kingozi, F. Wabwire-Mangen, D.S. Serwadda, C. Li, M. Meehan, M.J. Wawer, USA

C43 Rapid Assessment for Intervention Development

| Chairs: | Thierry E. Mertens, Gerald V. Stimson |
| Venue: | Satellite Hall 2000 |
| Time: | 11.00-12.30 |

529 Rapidly responding to HIV and AIDS - Can social science inform community and international interventions?
Chris Fitch*, G.V. Stimson, T. Rhodes, A. Ball, G. Weiler, R. Sujata, A. Ball, A. Perez-Gomez, UK

530 Mekong movements: Border areas HIV/AIDS prevention project
Gio Tran Minh*, L.A. Esposito Catherine, O. Souksavanh, Vietnam

531 Situation analysis of prostitution in Bobo Dioulasso, Burkina Faso and vulnerability of the sex workers in the context of the HIV epidemic
Michel Cartoux*, P. Huygens, M.D. Nikiema, G. Ido, A. Dembele, P. Van De Perre, Burkina Faso

532 Effectiveness of peer education and monitoring of the condom use by the sex workers in brothel settings in Bangladesh for prevention of HIV
Aniki Begum*, M.A. Qudus, F.K. Chowdhury Ury, Swarup Sarkar, M. Bloem, Nazrul Islam, Bangladesh

533 Peer education to reduce STI/HIV transmission in Mutare, Zimbabwe
Simon Machababe*, D. Mclean, R. Goma, D. Wilson, R. Sabatier, Zimbabwe

D41 Human Rights and Legal Challenges

| Chairs: | Ian Kramer, Miriam Maluwa |
| Venue: | Session Hall I |
| Time: | 11.00-12.30 |

534 Developing the human rights program for the AIDS prevention council in Jalisco, Mexico
Armando J. Diaz Camarena*, Jesus Martinez Serna, Juanita Martinez Lopez, Ana Rita Dueñas Martinez, Carmen Carcedo Aldrete, Patricia Campos Lopez, Mexico

535 Training HIV-positive people to document human rights violations in Asia: The APN+ human rights initiative
Susan Paxton*, B. White, Australia

536 Access to treatment: AIDS affected population in Costa Rica wins constitutional challenge
Antonio Matamoros*, L.G.M. Murillo Guillermo, M.F.G. Ganta Manuel, M.C.R. Marco Castillo, Costa Rica

537 Promoting the rights of prisoners: Condoms, bleach, needles, methadone and care in prisons
Ralf E.J. Jürgens, Canada

538 A human rights approach to reducing women’s vulnerability to HIV/AIDS
Daniel Wheelan, USA

539 Creation of an enabling and gender just legal environment as a prevention strategy for the spread of HIV/AIDS amongst women
Mandeep Dhillon, India

D42 Workplace – Promotion, Prevention and Protection

| Chairs: | Richard Constant Okuv, Anthony Pramvalratana |
| Venue: | Session Hall II |
| Time: | 11.00-12.30 |

540 Peer education among factory workers in Zimbabwe; providing a sustainable HIV prevention intervention
David Katzenstein*, W. McFarland, M. Mbelo, A. Latif, R. Macheke, J. Parsniet, M. Bassett, USA

541 AIDS, India and the trucking industry
Barun Kanjilal*, S. Forsythe, India

542 Protecting paradise: Tourism and AIDS in the Dominican Republic
Steven Forsythe*, J. Hasbún, M. Butler De Lister, UK

543 UK coalition back to work pilot project
Bec Clarkson, UK

544 Sexual networking and AIDS awareness program at the workplace: the case of oil locations in Nigeria

545 Grief at work: helping organizations cope with AIDS-related loss
Stuart Gibson*, A. Plotnick, D. Scott, USA

Skills Building workshops 11.00-14.30: see page 00 for details

NOTES

Pathway Symbols:  Gender  Human Rights
## A42 Animal Models for Vaccine Development

**Chairs:** Sam Avrett, Reinhard Kurth  
**Venue:** Session Hall III  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>546</td>
<td>Attenuated SIV vaccines: Safety and efficacy following heterologous challenge</td>
<td>Mark G. Lewis*, F. November; R. Desrosiers; Y. Lu; E. Rud; V. Hirsch; D. Birx, USA</td>
<td>11238</td>
</tr>
<tr>
<td>547</td>
<td>Role of b-chemokines in protective immunity against intrarectal SIVsm challenge of macaques</td>
<td>Rigmor Thorstensson*; R. Ahmed; C. Wilson; P. Pudkonen; Y. Wang; T. Lehner; G. Biberfeld, Sweden</td>
<td>11239</td>
</tr>
<tr>
<td>548</td>
<td>Recombinant vaccine-induced protection against the highly pathogenic SIVmac251 dependence on route of challenge exposure</td>
<td>Geneovetta Franchini, USA</td>
<td>21200</td>
</tr>
<tr>
<td>549</td>
<td>Protective T-cell mediated immunity induced by a consecutive HIV-1 DNA and avipox vaccine regimen</td>
<td>Stephen Kent*; A. Zhao; E.M. Dai; J.D. Chandler; H.L. Robinson; D.B. Boyle; I.A. Ramshaw, Australia</td>
<td>21198</td>
</tr>
<tr>
<td>550</td>
<td>Potent neutralization of primary HIV-1 isolates by antisera induced upon immunization with a recombinant protein expressing the native V1/V2 domain of gp120</td>
<td>Abraham Pinter*; O. Trochev; W.J. Honnen; Z. Wu; S. Reiken; M. Lewis; S.C. Kayman, USA</td>
<td>21194</td>
</tr>
<tr>
<td>551</td>
<td>Multi-subtype envelope-based DNA and protein immunization strategies for broadening immune responses to HIV-1</td>
<td>Susan W. Barnett*; Y. Sun; H.S. Legg; T.C. VanCott; J.R. Mascola; F.M. Sinangil, USA</td>
<td>21196</td>
</tr>
</tbody>
</table>

## B44 Neurological Complications of HIV

**Chairs:** Paola Cinque, Christina M. Marra  
**Venue:** Session Hall IV  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>558</td>
<td>Latest developments in neuropathogenesis</td>
<td>To be confirmed</td>
<td>32191</td>
</tr>
<tr>
<td>559</td>
<td>Animal models of HIV neuropathogenesis</td>
<td>Dominique Dormont</td>
<td>32192</td>
</tr>
<tr>
<td>560</td>
<td>Predictive markers for HIV-associated dementia and sensory neuropathy</td>
<td>Elizabeth Childs*; Justin C. McArthur; R.H. Lyles; E. Miller; B.A. Cohen; B.B. Chen; J. Mellors; J.C. McArthur, USA</td>
<td>32192</td>
</tr>
<tr>
<td>561</td>
<td>Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (Study ONAB 3001)</td>
<td>Bruce James Brew*; S.J. Brown; J. Catalan; N. Sacktor; M. Halman; W.T. Symonds; C. Romero; ONAB 3001 Study Team, Australia</td>
<td>32192</td>
</tr>
<tr>
<td>552</td>
<td>Introduction</td>
<td>J. Condra</td>
<td>552</td>
</tr>
<tr>
<td>553</td>
<td>S-1153, a new nonnucleoside reverse transcriptase inhibitor of HIV-1</td>
<td>Tamio Fujiwara*; A. Zhao; E.M. Dai; J.D. Chandler; H.L. Robinson; D.B. Boyle; I.A. Ramshaw, Australia</td>
<td>41181</td>
</tr>
<tr>
<td>554</td>
<td>Cellular pharmacology of the antiviral agents PMPA and PMEA in vitro and in vivo</td>
<td>Arnold Fridland*; B. Robbins; J. Rodman; C.C. Tsai; N. Bischofberger, USA</td>
<td>41175</td>
</tr>
<tr>
<td>555</td>
<td>A resistance surmountable HIV protease inhibitor effective against both wild-type and new analogs of HIV-1 protease</td>
<td>Yoshiaki Kiso*; M. Kishida; H. Matsumoto; S. Mizumoto; T. Kimura, Japan</td>
<td>41212</td>
</tr>
<tr>
<td>556</td>
<td>Abacavir (1592, ABC) prevents spread of HIV-1 in brain tissue of SCID mice with HIV-1 encephalitis</td>
<td>Jenae Limoges*; D.R. McAlmont; P. Persidsky; J. Rasmussen; E.R. Lanier; J. Reinhard; H.E. Gendelman, USA</td>
<td>41233</td>
</tr>
<tr>
<td>557</td>
<td>Anti-HIV activity, biochemistry, and pharmacokinetics of b-D-2',3'-dideoxy-2',3'-dideoxy-5-fluorocytidine (D-D4FC)</td>
<td>Raymond Schinazi*; L. Ma; J. Shi; D. Liotta; A. Faraj; J.P. Sommadossi, USA</td>
<td>41174</td>
</tr>
</tbody>
</table>

## A43 Pre-Clinical Drug Development

**Chairs:** D.J. Back, T. Smart  
**Venue:** Session Hall VII  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>552</td>
<td>Introduction</td>
<td>J. Gondra</td>
<td>552</td>
</tr>
<tr>
<td>553</td>
<td>S-1153, a new nonnucleoside reverse transcriptase inhibitor of HIV-1</td>
<td>Tamio Fujiwara*; A. Zhao; E.M. Dai; J.D. Chandler; H.L. Robinson; D.B. Boyle; I.A. Ramshaw, Australia</td>
<td>41181</td>
</tr>
<tr>
<td>554</td>
<td>Cellular pharmacology of the antiviral agents PMPA and PMEA in vitro and in vivo</td>
<td>Arnold Fridland*; B. Robbins; J. Rodman; C.C. Tsai; N. Bischofberger, USA</td>
<td>41175</td>
</tr>
<tr>
<td>555</td>
<td>A resistance surmountable HIV protease inhibitor effective against both wild-type and new analogs of HIV-1 protease</td>
<td>Yoshiaki Kiso*; M. Kishida; H. Matsumoto; S. Mizumoto; T. Kimura, Japan</td>
<td>41212</td>
</tr>
<tr>
<td>556</td>
<td>Abacavir (1592, ABC) prevents spread of HIV-1 in brain tissue of SCID mice with HIV-1 encephalitis</td>
<td>Jenae Limoges*; D.R. McAlmont; P. Persidsky; J. Rasmussen; E.R. Lanier; J. Reinhard; H.E. Gendelman, USA</td>
<td>41233</td>
</tr>
<tr>
<td>557</td>
<td>Anti-HIV activity, biochemistry, and pharmacokinetics of b-D-2',3'-dideoxy-2',3'-dideoxy-5-fluorocytidine (D-D4FC)</td>
<td>Raymond Schinazi*; L. Ma; J. Shi; D. Liotta; A. Faraj; J.P. Sommadossi, USA</td>
<td>41174</td>
</tr>
</tbody>
</table>

## B45 Bridging Session: Issues in Clinical Trial Design

**Chairs:** Lynda Dee, Markus Flepp  
**Venue:** Arena  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>565</td>
<td>What kinds of trials?</td>
<td>Ann Collier</td>
<td>565</td>
</tr>
<tr>
<td>566</td>
<td>The role of cohort studies</td>
<td>Andrew Phillips</td>
<td>566</td>
</tr>
<tr>
<td>567</td>
<td>Trials in developing countries</td>
<td>Praphan Phanuphak</td>
<td>567</td>
</tr>
<tr>
<td>568</td>
<td>The patients’ perspective</td>
<td>James Kreppner</td>
<td>568</td>
</tr>
</tbody>
</table>
### C44 Transgender Issues: Living with HIV, Prevention, Identity
**Chairs:** Camille Cabral, Julian Hows  
**Venue:** Session Hall V  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>569</td>
<td>Implications of living with HIV/AIDS as a transitioning transsexual woman</td>
<td>Danny Anderson, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>570</td>
<td>HIV-infection among transsexual sex workers from developing countries: A review of six years of activity of a reference center in Rome</td>
<td>Laura Spizzichino*, P. Gattari, M. Zaccarelli Mauro, S. Venezia, G. Rezza</td>
<td>Italy</td>
</tr>
<tr>
<td>571</td>
<td>The HIV hormone bridge: Connecting impoverished HIV+ transsexual sex workers to HIV medical care</td>
<td>James Grimaldi*, J. Jacobs, USA</td>
<td>USA</td>
</tr>
<tr>
<td>572</td>
<td>The health care issues of the HIV+ and HIV- incarcerated transgender community</td>
<td>Scott Goza, USA</td>
<td>USA</td>
</tr>
<tr>
<td>574</td>
<td>Mobilizing transgenders for HIV prevention through cultural presentation</td>
<td>Jose Sezon*, Alfeo Salcedo, Philippines</td>
<td>Philippines</td>
</tr>
</tbody>
</table>

### C45 Model-Based Evaluation of HIV Prevention Programmes
**Chairs:** Jane Galvao, Edward Kaplan  
**Venue:** Session Hall VI  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>576</td>
<td>Potential public health impact of offering post-exposure prophylaxis (PEP) for episodic high-risk sexual behaviour by men who have sex with men (MSM)</td>
<td>Grant Colfax*, E. Vittinghoff, K. MacQueen, J. Douglas, D. McKim, J. Tudden, S. Buchbinder, USA</td>
<td>USA</td>
</tr>
<tr>
<td>577</td>
<td>The effects of two years of harm reduction in Rome</td>
<td>Marina Davoli*, Annette Verster, Teresa Spada, Fabio Patruno, Fulvia Pascualini, Carlo Alberto Perucci, Massimo Arcà, Italy</td>
<td>Italy</td>
</tr>
<tr>
<td>579</td>
<td>Interaction of vaccine effectiveness and risky behaviour</td>
<td>Sally Blower</td>
<td>Canada</td>
</tr>
</tbody>
</table>

### D43 What We Are Told About AIDS: Media Response and Transformation
**Chairs:** Bunmi Makinwa, Simon Watney  
**Venue:** Session Hall I  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>586</td>
<td>Media impact/agreement between a NGO and a national newspaper: A successful experience of collaboration</td>
<td>Alejandro Brito, A. Diaz, C. Bonfi, M. Figueroa, M. Zozaya, Mexico</td>
<td>Mexico</td>
</tr>
<tr>
<td>587</td>
<td>Sensitizing print media to AIDS and reproductive health issues</td>
<td>Sadha Mohan, India</td>
<td>India</td>
</tr>
<tr>
<td>588</td>
<td>Developing a nationwide public service advertising on STD syndromes</td>
<td>Kathleen Cabal*, J. Fieras, C. Aquino, N. Villar, Philippines</td>
<td>Philippines</td>
</tr>
<tr>
<td>589</td>
<td>Using ethnic media to reach multiple language migrant communities in the Sydney region</td>
<td>Tadgh McMahon, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>590</td>
<td>Assessment of Moscow press participation in HIV/AIDS prevention</td>
<td>Elena V. Loubawa*, Vadim V. Pokrovsky, Russia</td>
<td>Russia</td>
</tr>
<tr>
<td>591</td>
<td>Trends of reporting on HIV/AIDS and mobile groups in the print media of Bangladesh: Can the media be an ally in altering the image of AIDS?</td>
<td>Joachim Victor Gemes*, Ela Barua, M. Bloem, Bangladesh</td>
<td>Bangladesh</td>
</tr>
</tbody>
</table>

### NOTES
- Pathway Symbol: Gender
### Mental Health and HIV

**Chair:** V. Sonnenberg-Schwan, Sussa Szabo  
**Venue:** Session Hall II  
**Time:** 13.00–14.30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>592</td>
<td>Counselling strategies: they work! Results from the Voluntary HIV Counselling and Testing (VCT) Study</td>
<td>Don Balmer*, Olga Grinstead; E. Van Praag; S. Gregorich; G. Sangiwa; C. Furlonge</td>
<td>USA</td>
</tr>
<tr>
<td>593</td>
<td>Confidentiality and couple HIV counselling encourage client disclosure of serostatus and risk behaviour: Results from the voluntary HIV counselling and testing study</td>
<td>Olga Grinstead*; A. Van Der Staten; G. San Giwa; M. Hegaz; USA</td>
<td>USA</td>
</tr>
<tr>
<td>594</td>
<td>The personal meanings and constructs attributed to being labelled with AIDS dementia complex</td>
<td>Irit Ben-Nissan*; K. O'Neill; B. Bren</td>
<td>Australia</td>
</tr>
</tbody>
</table>

### Cellular Immunity

**Chair:** Fernando Auñí, Angel Jaramillo  
**Venue:** Session Hall III  
**Time:** 15.00–17.00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>598</td>
<td>Control of HIV replication requires virus-specific helper and CTL function and levels of CTL activity are in equilibrium with viral burden</td>
<td>Spyros Kalams*; S.P. Buchbinder; M.J. Billingsley; E.S. Rosenberg; N. Jones; A.K. Trolia; B.D. Walker</td>
<td>USA</td>
</tr>
<tr>
<td>599</td>
<td>HIV-specific cytotoxic T lymphocytes (CTLs) in Thai exposed uninfected (EU) female sex workers (FSWs) are directed to multiple regions of HIV-1 subtype E</td>
<td>Busarawan Sriwanthana*; K.B. Bond; T.W. Hodge; C.P. Pau; T.D. Mastro; N.L. Young; K. Limpakamanjanarat</td>
<td>USA</td>
</tr>
<tr>
<td>600</td>
<td>HIV-1 specific cytotoxic T-lymphocyte responses in uninfected Kenyan prostitutes: Behavioural and immunologic correlates</td>
<td>Rupert Kaul*; K. Fowke; E. Ngagi; J. Ruthetford; K.S. MacDonald; F.A. Plummer</td>
<td>Kenya</td>
</tr>
<tr>
<td>601</td>
<td>Cross-clade envelope Gp160, Gag p55 and pol specific CD8+ CTL responses early following HIV-1 clade-B infection</td>
<td>Susan Wilson*; S.L. Pedersen; J. Kunich; G. Mazzara; J. Tagatia; C.L. Gelum; H.W. Sheppard</td>
<td>USA</td>
</tr>
<tr>
<td>602</td>
<td>HIV-1 specific cytotoxic T lymphocyte responses in uninfected Kenyan prostitutes: Behavioural and immunologic correlates</td>
<td>Rupert Kaul*; K. Fowke; E. Ngagi; J. Ruthetford; K.S. MacDonald; F.A. Plummer</td>
<td>Kenya</td>
</tr>
</tbody>
</table>

### Vaccines: Animal Models and Development

**Chair:** Lars O. Kalings, Edward K. Mbidde  
**Venue:** Session Hall VI  
**Time:** 15.00–17.00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>606</td>
<td>Introductory overview</td>
<td>Marc Girard</td>
<td></td>
</tr>
<tr>
<td>607</td>
<td>New approaches to an HIV vaccine</td>
<td>Emilio Emini</td>
<td></td>
</tr>
<tr>
<td>608</td>
<td>The pros and cons of live attenuated vaccines. Towards human trials with LAV</td>
<td>Charles Farthing</td>
<td></td>
</tr>
<tr>
<td>608.1</td>
<td>Pathogenicity of multiply deleted, live attenuated lentivirus vaccines</td>
<td>Ruth Ruprecht</td>
<td></td>
</tr>
</tbody>
</table>
**JUNE 30**

### C47: Tuberculosis and HIV in Developing Countries

**Chairs:** Peter Godfrey-Faussett, Nkanda Luo  
**Venue:** Session Hall IV  
**Time:** 15.00 - 17.00

- **609** The impact of HIV on transmission of tuberculosis (TB) in Ugandan households  
  David Guwatudde*; M.K. Nakeeta; C. Whalen; G. Bunkenya; A. Okwera; J. Elner; Uganda  
- **610** Trends of HIV-1 infection among pulmonary tuberculous adults, 1993 - 1997, Kampala, Uganda  
  Alphonse Okwera*; A. Luzze; P. Nsubuga; J.L. Johnson; C. Whalen; R. Mugyera; J. Elner; Uganda  
- **611** Increasing frequency of TB among staff in a South African hospital: Impact of the HIV epidemic on supply of health care  
  David Wilkinson*; C.F. Gilks; South Africa

### B46: HIV-Associated Neoplasia

**Chairs:** Alexandra M. Levine, Andres Schmilovich  
**Venue:** Session Hall VII  
**Time:** 15.00 - 17.00

- **617** Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated Kaposi's sarcoma (KS)  
  Sara Santambrogio*; A.L. Ridolfi; N. Tosca; M. Galli; C. Paravincini; M. Corbellino; Italy  
- **618** Topical 9-cis-Retinoic acid PanretinGel treatment of cutaneous AIDS-related Kaposi's sarcoma: Interim results of an international, placebo-controlled trial (ALERT 1057-503)  
  Neil Bodsworth*; On Behalf of the International Panretin KS Study Group; Intern, Australia  
- **619** North American phase 3 study (protocol L1057T-31) of PanretinGel (LGD1057, ALERT1057) for cutaneous AIDS-related Kaposi's sarcoma  
  Alvin Frie Oman-Kien*; M. Conant; USA  
- **620** HHV-8, proliferation, apoptosis and ploidy in epidemic (AKS), endemic (EKS), and classical (CKS) Kaposi's sarcoma (KS)  
  Epahata Kaaya*; Peter Biberfeld; E. Castanous-Velez; T. Heden; M. Stuzl; J.Z. Zou; J. Kline, Sweden  
- **621** Association of vitamin A deficiency with cervical dysplasia in the Women’s Interagency HIV Study (WIHS)  
  Audrey French*; M.H. Cohen; R.O. Semba; J.K. Burke; K.M. Weber; L.S. Massad; USA  
- **622** Case-control study of cervical cancer and HIV-infection in Abidjan, Côte d’Ivoire  
  Georgette Adjorlolo-Johnson*; A. Anhoux; K. Toure-Coulibaly; G. Laruche; G. Aissi; E. Unger; M. Honde; S. Vernon; A.E. Greenburg; S.Z. Wiktor; Côte d’Ivoire  
- **623** Incidence of squamous intraepithelial lesions (SIL) in HIV-infected women  
  Marie-Christine Delmas*; A. Agarossi; C. Bergeron; F. Meier; P. Supannachat; J. Paavonen; J.D. Poveda; J.A.R. Van Den Hoek; France  
- **624** Comparison of the amount of HPV 16 DNA in cervicovaginal secretions of HIV-infected and uninfected women, using quantitative competitive-polymerase chain reaction (QC-PCR)  
  Thomas Wright*; X.W. Sun; T.V. Ellerbrock; Chiasson; USA

### B47: Grand Rounds: Clinical Case Studies

**Chairs:** David Chipanta, Michel P. Glauser  
**Venue:** Arena  
**Time:** 15.00 - 17.00

- **625** Case presentations  
  Amalio Telenti  
- **626** Virologic failure  
  Joep Lange  
- **627** Treatment complications  
  Robert Schooley  
- **628** A case of HIV-infection in the developing world  
  Sin Yew Wong  
- **629** Natural history of HIV-associated disease under HAART  
  Diane Havlir
Thursday, July 2

ORAL SESSIONS

C48 Bridging Session: Microbicides: Towards a New Paradigm

- Chairs: Lori Heise, Joseph Perriens
- Venue: Session Hall V
- Time: 15.00–17.00

- Economic and marketing issues
  - Lieve Fransen

- State-of-the-art: clinical research
  - Zeda Rosenber

- Pre-clinical overview: what possibilities exist
  - Mark Wainberg

- Case study for political advocacy: Zimbabwe
  - Priscilla Mhisharabwi

- Discussant: trials
  - Gita Ramjee

- Discussant: consumer perspective
  - Kanokwan Gaye Tharawan

- Discussant: government perspective
  - Debra Birnkrant

D45 Implications of New Treatments at Individual and Population Level

- Chairs: Enzio Dos Santos Filho, C. Perez
- Venue: Session Hall I
- Time: 15.00–17.00

- AIDS, virtually normal now? Protease inhibitors and the end of consensus
  - Meuriestyn Horton, UK

- Do people fail drugs, or do drugs fail people? The discourse of “adherence”
  - Agnes Harley*, J.D. Davids, J.M. Maskovsky, J.S. Shull, USA

- T.H.E. (Tools for Health and Empowerment) course: A unique disease management program
  - W. David Hardy*, Ebere Igboko, M.M.L. Rice, K. Anastas, E.F. Igboko, A. Torres, P.J. Welch, S.D. Goodwin, USA

- The impacts of combination therapies on the lives of people with HIV
  - Peter Weaterburn*, W. Anderson, F.C.I. Hickson, P.G. Keogh, UK

- Treatments, intimacy and disclosure in the sexual practice of HIV-infected adults in Australia
  - Michael Bartos*, D. Ezzy, K. McDonald, D. O'Donnell, R. de Visser, Australia

- HIV/AIDS preventive attitudes and behaviour of French and Swiss gay men in the era of new treatments. A comparison of two national surveys
  - Philippie Adam*, F. Moreau-Gruet, F. Hamers, M.C. Delmas, J.B. Brunet, F. Dubois-Arber, France

- HAART, attitudes, and risk behaviour among serodiscordant male couples
  - Robert H. Remien*, G. Wagner, A. Carballejo Dieguez, C. Dolenz, USA

- New therapies for HIV and sexual risk behaviour among gay men in London, UK
  - Graham Bolding*, J. Elford, L. Sheer, M. Maguire, J. Elford, UK

D46 Resource Mobilisation: Where Will the Money Come From?

- Chairs: Sally Cowall, Sofia Mukaso-Monico
- Venue: Session Hall II
- Time: 15.00–17.00

- Sustainability beyond donor aid
  - Soledad Atayan, Philippines

- The Global Business Council on HIV/AIDS (GBC)
  - Jose LLados*, Ben Plumley, J. Hussey, UK

- Amounts, patterns and trends of national and international financing of the response to HIV/AIDS in developing countries, 1996–1997
  - Daniel Tarantola*, G. Emberg, USA

- European funding for HIV in the developing world
  - Ian Pronk

- North American Funding for HIV in the developing world
  - Steve Morin

- Funders concerned about AIDS on philanthropic funding
  - Paul di Donato

- A unique Zululand industry joint venture response to the needs of employees with HIV/AIDS
  - Jennifer Rogers, South Africa
SB 41  Gestión clínica en contextos de recursos limitados
(en español)
Venue: Room E  
Time: 11.00–14.30
La escasez de recursos en el Sur supone un reto a la hora de actuar en los casos de VIH. Mediante el formato de grandes rondas clínicas, los participantes analizarán temas tales como la monitorización de infecciones, el tratamiento de infecciones oportunistas, la utilización de terapias antirretrovirales y cuidados paliativos. El objetivo de esta sesión es el de proporcionar las técnicas necesarias para evaluar el desarrollo apropiado de una acción en el tratamiento clínico. Este taller está dirigido al personal clínico y al área de la salud, y a las personas afectadas por el VIH.
Impartido por: Enio Tavora dos Santos Filho, Grupo Pela Vida, Brasil; José Gábel, Hospital Clinic of Barcelona, Spain; Patty García, National AIDS Control Programme, Peru; Carlos del Río, Emory University, USA

SB 42  Building Strategic Alliances to Help Sustain Programme and Organisational Impact
Venue: Room F  
Time: 11.30–14.00
Most organisations face financial constraints. Although donor funding may be available to start a programme what happens when a project changes, or the funding decreases or ends? A rising demand for funding for both prevention and care programmes has emphasised the need to assess existing patterns of resource use and to explore alternative ways of sustaining programmes. One way organisations can work towards sustaining effective programmes is by building alliances, or actively collaborating with other organisations, not only NGOs and donors but the private sector, church, local and national government. This workshop will focus on helping participants plan a strategy to develop working relationships/alliances.

SB 43  Développement de programmes de diététique dans les contextes défavorisés en ressources (en français)
Venue: Room G  
Time: 11.30–14.00
Pour beaucoup de personnes vivant avec le VIH/sida, la seule thérapie d’accès relativement simple reste la nutrition. À travers cet atelier, les participants tenteront de dégager des stratégies pratiques afin de mettre en place des programmes de nutrition en mesure de répondre aux besoins des personnes vivant avec le VIH/sida dans des milieux défavorisés. On recommande aux personnes vivant avec le VIH/sida ainsi qu’aux formateurs et au personnel médical d’assister à cet atelier.
Facilitated by: George Carter, Direct AIDS Alternative Information Resources, USA; Maguette Ndiaye, BASICS/USAID, Senegal

SB 44  Clinical Management in Resource-Poor Settings
Venue: Room H  
Time: 11.30–14.00
The limited resources in the South present challenges in responding clinically to HIV. Using a clinical grand rounds format, participants will explore issues of monitoring the infection, managing opportunistic infections, using antiretroviral therapies, and palliative care. This session is designed to provide skills in assessing appropriate courses of action in clinical management. Clinicians, health care providers and persons affected by HIV are encouraged to attend.
Facilitated by: Tuti Merati, Citra Usad, Indonesia; Elly Katabira, Makerere University, Uganda; Mark Ottenweller, Soweto Hope, South Africa/USA
POSTER SESSIONS

Track A: Basic Science

41101 Interactions of secretory IgA with HIV-1 gp120: Potential pitfalls of anti-HIV ELISA using saliva
Susan Jackson*; S.J. Prince; R. Kulhavy; J. Mestecky, USA

41102 HIV-screening with the Elesys automated analyser: Combined testing for anti-HIV and HIVAg within 18 minutes
Frédéric Donnet*; B. Umpreier; E. Hoess; E. Faatz, Germany

41103 Detection of memory T cells in HIV+ individuals: Cytokine producing lymphocyte precursors (CPLp)
Kendall A. Smith*; G. Chiozzi; F. Pilaro; E.L. Jacobson; R. Emer; USA

41104 Universal peptide for detection of HIV-1 group M and group O infections in rapid immunoassay
Azal Chowdhury*; J.M. Lovchik; M.A. Childs; D. Bernstein, USA

41105 Evaluation of a locally produced particle agglutination assay for detection of antibodies to HIV-1
Wilfred James Njoroge*; C.W. Mutura; W.A. Mwangi; N. Sakagami; K. Kakimoto; P.M. Takei; T. Kunimura, Japan

41106 Murex HIV-1.2.O is a highly sensitive and specific assay for antibodies to HIV-1/M, HIV-1/O and HIV-2
Richard Briscoe*; T. Carter; K. Francis; J. Lovell; B. Rodgers; D. Trotter; P. Weston, UK

41107 Detection of HIV-1 Subtypes by a new rapid immunochromatographic test
Hinoyasu Ara*; S. Devane; T. Kosaka; K. Takeda, Japan

41108 Validation study of HIV testing in urine samples
David Mabey*; John Changalucha; B. West; D. Ross; R. Balira; J. Todd; T. Boerma; D. Mabey, UK

41109 Predictors of HIV infection among professional blood donors with Western Blot Indeterminate results (WBI)
Usa K. Baveja*; D. Chattopadhyay; R.K. Aggarwal; V. Doda; S. Kumari; J. Sokhey, India

41110 HIV antibody activity measurement how to distinguish primoinfected from old infected patients using one ELISA test adapted to AYSYM Automatic Christopher Paxan; A. Lemeur; B. Evreux; S. Kouyoumdjian; C. Ungsidhapand; J. Lange; D. Cooper; P. Phanuphak, Thailand

41111 Identification of a new virus-associated epitope inducing antibody responsible for the non-progression to AIDS
Pascale Galea*; C.R. Steinhart; P. Willem; N. Profizi; C. Leconte; J.C. Oermann; France

41112 In vitro HIV-1 antibody induction. Testing of the "Shilov Tube" method of Alain Sauder; R. Bieche; A. Ruat; C. Desvergne; J.C. Chevrier, France

41113 A new generation of HIV-diagnostics assay: Results of the evaluation of the Enzymun-Tests HIV combi
Elke Faatz*; F. Donie; W. Mehior; B. Umpreier; C. Seidel, Germany

41114 Performance of calypte HIV-1 urine EIA in three US populations
Dean Schoer*; Y. Mitteco; T. Gottfried; M. Kanar, USA

41115 Performance of an HIV-1, HIV-2 and HIV-1 group O immunoassay on the Abbott ARCHITECT 2000 analyzer
William Black*; S. Steward; A. Hoffmann; J. Prosko; L. Xu, USA

41116 A new approach to flow cytometry-based CD4 T-cell enumeration for absolute and percentage values
Michèle Bergeron*; F.F. Mandly; T. Ding; S. Phaneuf, Canada

41117 Sensitivity evaluation of Vironostika Uni-Form II plus O with samples from Thailand
Thippawan Chuenchitra, Thailand

41118 HIV-screening with the Elesys automated analyser: Testing for HIVAg within 18 minutes with a sensitivity of 3 pg/ml
Urban Schmitt*; D. Schlieper; B. Umpreier; W. Melchor; E. Faatz, Germany

41119 Anti HIV-1/2 mass testing, what should be done?
Alexandre M. Oliveira*; C.C. Hofling; M.C. Ramos; S.A.A. Chaves, Brazil

41120 Rapid, 3rd generation one-step immunoassay for HIV antibodies, useful in developing countries
Jesus Benitez; O. Ganzo; J. Rivero; J. Cavilondo, Cuba

41121 Seroprevalence of HIV-infection among street children in Maiduguri
Edemnang D. Okpudo-Itata*; T.O. Harry; M. Bulterys; A. Abimiku, Nigeria

41122 Sensitivity of HIV-1 group M Western blot for the confirmation of HIV-1 group O infections, according to different interpretation criteria
Charlotte Ngansop*; Seraphin Kuade; L. Zikeng; M. Kengne; L. Kaptue, Cameroon

41123 Prevalence and control of STDs/HIV among commercial sex workers (CSW)
Jyotesh Shrestha*; V.L. Gurubacharya, Nepal

41124 Modifications in the DTH reaction in HIV-infected individuals
Kamen Plochev, Bulgaria

41125 Evaluation of a fast method (HIVSAV•) for serologic diagnosis of HIV-1 e 2
Drainio Barreira*; G. Silva; H.M.V. Oliveira; Y. Bravin, Brazil

41126 Immunological monitoring in HIV-infection
Yuri Mitin*; El. Zhmushko; A.N. Malkov, Russia

41127 Field evaluation of the HIV-1 Amplicor Monitor and NucliSens quantitative HIV-1 RNA PCR assay in persons infected with HIV-1 subtype A in Abidjan, Côte d'Ivoire
John Niangou Song*; M. Kalou; C. Blie; M.Y. Borget; M. Morokro; E.R. Ekpini; P. Ghys; A.E. Greenberg; S.Z. Wiktor, Côte d'Ivoire

41128 Comparative evaluation of amplicor HIV-1 monitor with added primer set with quantiplex v2.0 HIV RNA assay and the nuclisens for quantitation of HIV-1 RNA in a Thai study population, primarily infected with subtype E
Sasiwimol Ubolyam*; K. Ruxrungtham; G.J. Weverling; C. Ungsudhaphand; J. Lange; D. Cooper; P. Phanuphak, Thailand

41129 High throughput assay for sensitive detection of HIV-1 RNA of diverse origins, including type O strains
Gratina Giachetti*; D. Kolk; J. Dockter; J.P. Knowlton; R. Wang; S. Hotaling; S. McDonough, USA

41130 Sensitivity, linear range and performance of HIV-1 subtypes of the COBASAMPLICOR HIV-1 monitor test
Conchita Pletcher*; D. De Bonville; J. Wang; K. Lalavalle; A. Chutoransky; K. Arch; A. Wang, USA